Privi Speciality Chemicals Ltd

Privi Speciality Chemicals Ltd has announced a record date of July 31, 2026, for the final dividend. This follows the Board of Directors' meeting on May 11, 2026, where the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, were approved. The board recommended a final dividend of ₹10 (100%) per equity share of ₹10 each for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting. The 41st Annual General Meeting will be held on August 07, 2026.

Privi Speciality Chemicals Ltd's Board of Directors, in its meeting on May 11, 2026, approved the re-appointment of M/s. Aneja Associates as the Internal Auditor and M/s. Kishore Bhatia & Associates as the Cost Auditors for the financial year 2026-27. The board also approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, recommended a final dividend of ₹10 (100%) per share, and re-appointed Mr. Bhaktavatsala Rao Doppalapudi as an Executive Director for 3 years. The 41st Annual General Meeting will be held on August 07, 2026, with a record date of July 31, 2026, for dividend entitlement.

Privi Speciality Chemicals Ltd's board re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director (Whole-time Director) for 3 years, effective August 13, 2026, subject to shareholder approval. The board also approved audited financial results for the year ended March 31, 2026, recommended a final dividend of ₹10 per share, and re-appointed internal and cost auditors. The 41st Annual General Meeting will be held on August 7, 2026, with a record date of July 31, 2026, for dividend entitlement.

Privi Speciality Chemicals Ltd's board approved a final dividend of ₹10 (100%) per equity share of ₹10 each for the financial year 2025-26, subject to shareholder approval at the upcoming 41st Annual General Meeting. The board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Other approvals included the re-appointment of an Executive Director and the re-appointment of Internal and Cost Auditors.

Privi Speciality Chemicals Ltd's board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They recommended a final dividend of ₹10 (100%) per share for FY26, subject to shareholder approval. The board also approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years and re-appointed M/s. Aneja Associates and M/s Kishore Bhatia & Associates as Internal and Cost Auditors, respectively, for FY27. The 41st Annual General Meeting will be held on August 07, 2026, with a record date of July 31, 2026.

Privi Speciality Chemicals Ltd. announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved the results at their meeting on May 11, 2026, and recommended a final dividend of ₹10 (100%) per equity share of ₹10 each for the financial year 2025-26, subject to shareholder approval. The board also approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as an Executive Director and the re-appointment of M/s. Aneja Associates and M/s Kishore Bhatia & Associates as Internal and Cost Auditors, respectively. The 41st Annual General Meeting will be held on August 07, 2026, with a record date of July 31, 2026, for dividend entitlement.

Privi Speciality Chemicals Ltd. has received an observation letter with 'no objection' from BSE Limited on May 06, 2026, regarding the proposed scheme of amalgamation between PSCL, PFSPL, and PBPL. This follows an earlier intimation on December 19, 2025, and a similar letter from the National Stock Exchange of India Limited. The scheme is subject to applicable regulatory and other approvals. The observation letter is available on the company's website.

Privi Speciality Chemicals Ltd. has received a No Objection Letter from the National Stock Exchange of India (NSE) regarding the proposed scheme of amalgamation between PSC, PFSpL, and PBPL, along with their respective shareholders and creditors. This follows the company's earlier intimation on December 19, 2025, about the Board's approval of the scheme. The observation letter from BSE is still awaited. The scheme remains subject to applicable regulatory and other approvals.

Privi Speciality Chemicals Ltd has scheduled a Board of Directors meeting on May 11, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider the declaration of a final dividend on equity shares. The trading window, which closed on April 1, 2026, will reopen on May 14, 2026.

Privi Speciality Chemicals Ltd has subscribed towards the equity share capital in the joint venture company, Prigiv Specialties Private Limited. This is in accordance with the Joint Venture Agreement and Amendment Agreements entered into with Givaudan SA, Switzerland. The Board of Directors of Prigiv Specialties Private Limited had approved the circular resolution for the allotment of Equity Share Capital on March 26, 2026. The Paid-up Capital of the Joint Venture Company post-allotment is as follows: Privi Speciality Chemicals Limited: INR 2,55,00,000 (49%), Givaudan SA, Switzerland: INR 2,45,00,000 (51%).